查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1972085

抗菌药物抗药性诊断市场：按技术、产品类型、测试类型、检体类型、病原体、应用和最终用户划分－2026年至2032年全球预测

Antimicrobial Resistance Diagnostic Market by Technology, Product, Test Type, Sample Type, Pathogen, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗菌药物抗药性诊断市场价值将达到 50.7 亿美元，到 2026 年将成长至 54 亿美元，到 2032 年将达到 79.8 亿美元，复合年增长率为 6.69%。

主要市场统计数据
基准年 2025 50.7亿美元
预计年份：2026年 54亿美元
预测年份 2032 79.8亿美元
复合年增长率 (%) 6.69%

这是一份简明扼要的抗生素抗药性诊断策略指南。它提出了一个框架，用于分析影响近期决策的不断变化的临床、技术和製度因素。

抗菌素抗药性（AMR）已从公共卫生问题演变为医疗保健系统、诊断公司和生命科学机构面临的策略挑战。能够检测抗药性机制并指导合理治疗的诊断平台已成为临床决策、合理使用抗菌药物方案和药物开发平臺的核心。随着检测网路的现代化以及临床医生对快速、可操作结果的需求，诊断领域正朝着结合分子精准性、表型背景和强大数据分析能力的整合解决方案方向发展。

诊断技术的融合、定序技术的进步以及以服务为导向的商业模式的重大变革，正在重新定义临床和商业性的优先事项。

在抗菌药物抗药性（AMR）诊断领域，正在发生多项变革性变化，这些变化正在重新定义产品开发的重点和市场进入策略。首先，诊断领域正朝着「诊断融合」的方向发展，即基因组分析方法（例如次世代定序）与快速分子检测和质谱分析相结合。这种融合模式兼顾了全基因组或靶向定序的全面概览、基于PCR的检测方法的速度和临床效用以及质谱分析的表型分辨率，使临床医生能够在临床可接受的时限内获得鑑定和抗药性标记数据。

对 2025 年关税措施将如何促进整个诊断价值链的供应链多元化、采购条款重新谈判和製造地重组进行实际评估。

美国将于2025年实施新的关税措施和贸易政策调整，将进一步增加抗菌药物抗药性（AMR）诊断供应链中製造商、经销商和临床实验室的营运复杂性。关税带来的成本压力正对设备采购、试剂采购和耗材补充产生连锁反应，迫使各机构重新评估筹资策略、供应商多元化和库存管理方法。在许多情况下，采购团队需要在短期成本增加和长期营运韧性之间寻求平衡。

透过对技术、产品、测试类型、最终用户、应用、检体类型和病原体领域进行详细的細項分析，我们制定有针对性的产品和市场策略。

市场区隔的详细分析揭示了临床需求、技术可行性和商业性机会的交汇点。目前正在研究的技术包括质谱、微阵列平台、次世代定序和聚合酵素链锁反应(PCR)。在次世代定序领域，长读长定序和短读长定定序的互补优势在阐明抗药性决定因素和建立监测系统方面备受重视。从产品角度来看，市场包括仪器、试剂和耗材，以及不断成长的软体和服务层。软体和服务领域进一步细分为咨询和支援服务，旨在帮助使用者实现复杂的工作流程。

影响招聘管道、监管要求和商业性策略的区域趋势（美洲和南美洲、欧洲、中东和非洲以及亚太市场）

区域趋势显着影响抗菌药物抗药性（AMR）诊断领域的应用曲线、调节路径和商业模式。在美洲，先进的检查室基础设施、一体化的医院网路和健全的公共卫生监测计画推动了对高通量标准解决方案和快速分子检测的需求。区域报销框架和机构采购行为往往强调已验证的临床效用以及与合理抗菌药物使用目标的明确关联，这可能有利于那些能够检验对患者疗效产生可衡量影响的供应商。

在竞争与合作并存的企业间动态中，成熟企业的规模与敏捷的创新者携手合作，推动技术应用与服务主导的差异化。

在先进医疗诊断领域，竞争格局呈现既有成熟的生命科学集团，也小规模、专注于创新的创新企业并存的局面。现有的诊断设备製造商利用涵盖设备、耗材和整合资讯系统的广泛产品组合，提供端到端的解决方案，以优化工作流程并满足法规遵循要求。这些大型公司通常会在全球服务网路、品管系统和上市后监测能力方面投入大量资金，以确保医院系统和标准实验室能够满足其对连续性和扩充性的需求。

促进推广应用的实用建议：产品模组化、可互通的分析技术、强大的供应链和基于证据的商业化。

产业领导者应采取平衡策略，将技术创新与切实可行的商业性执行相结合，以掌握抗菌药物抗药性（AMR）诊断领域的机会。首先，他们应优先考虑模组化产品架构，以实现跨平台试剂标准化，并简化跨多个司法管辖区的监管申报流程。此类设计可降低客户的整体拥有成本，并增强製造商应对区域采购和关税压力的柔软性。其次，他们应投资于可互通的软体和分析技术，将基因组和分子层面的分析结果转化为简洁明了的临床见解。这可减轻检查室和临床人员的认知负担，并加快决策速度。

本报告的研究采用了稳健的多方法研究设计，结合了对主要相关人员的访谈、二手证据的整合、资料三角测量和情境分析，以确保方法的严谨性和相关性。

本报告的研究整合了多个资料收集和检验层级，以确保调查方法的严谨性和相关性。主要研究包括对临床实验室主任、采购经理、诊断产品经理和公共卫生官员进行结构化访谈，以收集关于技术采纳、采购限制和营运重点的第一手观点。此外，还与服务供应商和技术专家进行了对话，以了解不同检测环境中的挑战和支援需求。

对决定不断发展的 AMR 诊断环境成功的技术要求、供应链实际情况和策略重点进行综合分析。

总之，抗菌药物抗药性诊断领域已进入关键阶段，技术能力、服务整合和供应链韧性正在决定竞争优势。先进的定序、快速分子检测和质谱分析各自发挥互补作用，而软体和咨询服务对于将复杂的检测结果转化为临床适用的建议也变得日益重要。监管现代化、抗菌药物管理要求和采购趋势正在影响医院、参考实验室和研究机构的采纳路径。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：抗菌素抗药性诊断市场：依技术划分

  • 质谱分析
  • 微阵列
  • 次世代定序
    • 长读长定定序
    • 短读定序
  • 聚合酵素链锁反应（PCR）

第九章：抗菌素抗药性诊断市场：依产品划分

  • 装置
  • 试剂和耗材
  • 软体和服务
    • 服务
      • 咨询服务
      • 支援服务
    • 软体

第十章：按检测类型分類的抗菌素抗药性诊断市场

  • 基因分型
    • 标靶检测
    • 全基因测序
  • 表型检测

第十一章：按检体类型分類的抗菌素抗药性诊断市场

  • 血液检体
  • 呼吸道检体
  • 尿液检体
  • 伤口拭子

第十二章：按病原体分類的抗菌素抗药性诊断市场

  • 真菌
  • 革兰氏阴性菌
  • 革兰氏阳性菌

第十三章：抗菌素抗药性诊断市场：依应用划分

  • 人类诊断
  • 药品和生物製药
  • 兽医诊断

第十四章：抗菌素抗药性诊断市场：依最终用户划分

  • 学术和研究机构
  • 诊断中心
  • 医院和诊所
  • 参考测试机构

第十五章：抗菌素抗药性诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：抗菌药物抗药性诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 抗菌药物抗药性诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国抗菌素抗药性诊断市场

第十九章：中国抗菌药物抗药性诊断市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bruker Corporation
  • Danaher Corporation
  • QIAGEN NV
  • Roche Diagnostics
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Vela Diagnostics
Product Code: MRR-2B5802CFEB38

The Antimicrobial Resistance Diagnostic Market was valued at USD 5.07 billion in 2025 and is projected to grow to USD 5.40 billion in 2026, with a CAGR of 6.69%, reaching USD 7.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.07 billion
Estimated Year [2026] USD 5.40 billion
Forecast Year [2032] USD 7.98 billion
CAGR (%) 6.69%

A concise strategic orientation to antimicrobial resistance diagnostics that frames the evolving clinical, technological, and institutional drivers shaping near-term decision-making

Antimicrobial resistance (AMR) has intensified from a public health concern into a strategic challenge for healthcare systems, diagnostics companies, and life sciences organizations. Diagnostic platforms that detect resistance mechanisms and guide appropriate therapy are now central to clinical decision-making, antimicrobial stewardship programs, and drug development pipelines. As laboratory networks modernize and clinicians demand faster, more actionable results, the diagnostic landscape is shifting toward integrated solutions that combine molecular precision, phenotypic context, and robust data analytics.

The convergence of advanced sequencing, rapid polymerase chain reaction (PCR) assays, mass spectrometry, and bioinformatic services has elevated the role of diagnostics from a confirmatory tool to a predictive instrument that shapes clinical pathways. Meanwhile, institutional imperatives-such as reducing hospital-acquired infections, improving antimicrobial use, and meeting regulatory reporting requirements-are re-prioritizing investments across hospitals, reference laboratories, and academic centers. These forces are being amplified by increasing cross-sector collaboration among diagnostic developers, pharmaceutical manufacturers, and governmental public health entities.

Against this backdrop, strategic leaders must assess not only the technical performance of diagnostic modalities but also how procurement, supply chains, regulatory frameworks, and payer dynamics influence adoption. The following sections unpack transformative shifts, regulatory and trade impacts, segmentation-level insights, regional opportunities and constraints, competitive dynamics, and pragmatic recommendations for organizations navigating the AMR diagnostics environment.

Critical transformative shifts in diagnostic convergence, sequencing advances, and service-oriented commercial models that are redefining clinical and commercial priorities

The landscape for AMR diagnostics is undergoing several transformative shifts that together redefine product development priorities and market access strategies. First, there is a clear movement toward diagnostic convergence where genomic approaches such as next generation sequencing are complemented by rapid molecular testing and mass spectrometry. This blended model balances the comprehensive overview afforded by whole genome or targeted sequencing with the speed and clinical utility of PCR-based assays and the phenotypic resolution of mass spectrometry, enabling clinicians to obtain both identification and resistance marker data within clinically relevant timelines.

Second, the maturation of long read sequencing technologies alongside short read approaches is unlocking new capabilities for resolving complex resistance loci, plasmids, and structural variants that were previously opaque to routine testing. As informatics pipelines and databases improve, genomic outputs are becoming more actionable, supporting outbreak detection, transmission mapping, and refined susceptibility predictions. Third, the role of software and services is expanding from backend analytics to front-line decision support; consultancy and support services are increasingly bundled with instruments and consumables to accelerate adoption and demonstrate return on investment to end users.

Fourth, the rise of decentralized testing models-driven by diagnostic centers and point-of-care initiatives-demands robust, easy-to-use systems and streamlined reagent supply chains. Finally, macro-level forces such as regulatory modernization, public-private stewardship initiatives, and funding directed at surveillance infrastructure are realigning incentives. Collectively, these shifts are creating an environment in which integrated, interoperable diagnostics offerings that deliver speed, accuracy, and actionable interpretation will command competitive advantage.

A pragmatic assessment of how 2025 tariff measures are catalyzing supply chain diversification, procurement renegotiation, and manufacturing realignment across diagnostic value chains

The introduction of new tariff measures and trade policy adjustments in the United States in 2025 has introduced an additional layer of complexity for manufacturers, distributors, and clinical laboratories engaged in the AMR diagnostics supply chain. Tariff-induced cost pressures have ripple effects across instrument procurement, reagent sourcing, and consumables replenishment, prompting organizations to reassess sourcing strategies, supplier diversification, and inventory management practices. In many cases, procurement teams are balancing the trade-offs between short-term cost increases and long-term operational resilience.

These trade-related frictions are accelerating supply chain strategies that prioritize geographic diversification and local manufacturing capability. Some manufacturers are evaluating onshoring or nearshoring of critical reagent production to reduce exposure to tariff volatility and shipping disruptions. Others are renegotiating distributor agreements to insulate downstream customers from price spikes while preserving service continuity. For clinical laboratories and health systems, the immediate operational response often includes renegotiated contracting terms, longer-term supply agreements, and targeted inventory buffering for high-use reagent lines.

In parallel, there is an observable shift in vendor selection criteria where total cost of ownership, supplier risk metrics, and lifecycle service commitments gain prominence. For product developers, tariff pressures underscore the importance of modular instrument designs, reagent standardization across platforms, and ecosystem partnerships that can smooth cross-border supply constraints. Overall, the 2025 tariff environment has acted as a catalyst for structural supply chain changes and strategic re-prioritization across the diagnostics value chain.

In-depth segmentation insights across technology, product, test type, end-user, application, sample type, and pathogen domains to guide targeted product and market strategies

A granular view of market segmentation illuminates where clinical demand, technological capability, and commercial opportunity intersect. Technologies under active study include mass spectrometry, microarray platforms, next generation sequencing, and polymerase chain reaction; within next generation sequencing, both long read sequencing and short read sequencing are being evaluated for their complementary strengths in resolving resistance determinants and enabling surveillance. From a product standpoint, the market comprises instruments, reagents and consumables, and an expanding layer of software and services; the software and services domain further breaks down into consulting services and support services that help institutions operationalize complex workflows.

Test-type distinctions continue to matter for adoption patterns. Genotypic tests, which include targeted assays and whole genome sequencing, provide molecular-level insights and are increasingly used for resistance mechanism detection and epidemiologic tracing, while phenotypic tests remain essential for confirming susceptibility and guiding immediate therapeutic decisions. End users range from academic and research institutions to diagnostic centers, hospitals and clinics, and reference laboratories; each category has distinct purchasing cycles, validation requirements, and throughput expectations that influence product design and commercial outreach.

Applications span human diagnostics, pharmaceutical and biopharmaceutical research, and veterinary diagnostics, reflecting the One Health perspective that links human, animal, and environmental resistance dynamics. Sample types in routine workflows include blood samples, respiratory samples, urine samples, and wound swabs, with each specimen class imposing unique pre-analytical and analytical constraints. Pathogen focus covers fungi, gram negative bacteria, and gram positive bacteria, each presenting different resistance mechanisms and diagnostic sensitivity challenges. Together, these segmentation dimensions provide a roadmap for tailoring product features, regulatory strategies, and commercialization tactics to meet heterogeneous clinical and research needs.

Regional dynamics that influence adoption pathways, regulatory requirements, and commercial approaches across Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics significantly shape adoption curves, regulatory pathways, and commercial models in the AMR diagnostics space. In the Americas, advanced laboratory infrastructure, integrated hospital networks, and strong public health surveillance programs create demand for both high-throughput reference solutions and rapid molecular tests. Reimbursement frameworks and institutional purchasing behaviors in this region often favor validated clinical utility and clear linkage to antimicrobial stewardship goals, which can favor suppliers able to demonstrate measurable impact on patient outcomes.

In Europe, Middle East & Africa, variability in healthcare funding, laboratory capacity, and regulatory environments creates a diverse set of entry strategies. High-income European markets prioritize conformity to stringent regulatory and quality standards and often require local validation and interoperability with electronic health records. In several countries across the broader region, public health initiatives and donor-funded programs are driving investment in surveillance and laboratory strengthening, opening opportunities for scalable, ruggedized systems suitable for decentralized settings.

The Asia-Pacific region exhibits a combination of rapid adoption in urban centers, significant investment in genomic and molecular capabilities, and a large base of clinical laboratories with variable resource profiles. Manufacturers targeting this region benefit from flexible product configurations that accommodate both high-throughput centralized labs and decentralized diagnostic centers. Across all regions, partnerships with local distributors, attention to regulatory timelines, and sensitivity to procurement cycles are critical determinants of commercial success.

Competitive and collaborative company dynamics showing how incumbent scale and nimble innovators together drive technological adoption and service-led differentiation

Competitive dynamics in the AMR diagnostics arena are characterized by a mix of established life science conglomerates and smaller specialized innovators. Incumbent diagnostics manufacturers leverage broad portfolios that span instruments, consumables, and integrated informatics to offer end-to-end solutions for workflow efficiency and regulatory compliance. These larger firms typically invest heavily in global service networks, quality systems, and post-market surveillance capabilities that reassure hospital systems and reference laboratories seeking continuity and scalability.

At the same time, agile technology companies and start-ups are driving innovation through focused advances in sequencing chemistry, rapid PCR assays, and interpretation software. Their strengths lie in rapid iteration, niche clinical validation studies, and partnerships with academic centers that accelerate clinical evidence generation. Collaboration between incumbents and innovators is increasingly common, enabling the scaling of novel assays while benefiting from established distribution and regulatory expertise.

Strategic alliances with pharmaceutical and biopharmaceutical firms are also prominent, as companion diagnostics and resistance profiling become integral to drug development and clinical trials. Moreover, an emerging services ecosystem-including consulting and support offerings-helps institutions implement complex workflows and extract value from rich genomic and phenotypic data. For stakeholders, competitive positioning now depends on the ability to combine technological differentiation with demonstrable clinical utility and robust service commitments.

Actionable and pragmatic recommendations for product modularity, interoperable analytics, resilient supply chains, and evidence-driven commercialization to accelerate adoption

Industry leaders should pursue a balanced strategy that aligns technological innovation with pragmatic commercial execution to capture opportunities in AMR diagnostics. First, prioritize modular product architectures that enable cross-platform reagent standardization and simplify regulatory submissions across multiple jurisdictions. Such designs reduce total cost of ownership for customers and increase flexibility for manufacturers to adapt to regional procurement and tariff pressures. Second, invest in interoperable software and analytics that translate genomic and molecular outputs into concise clinical intelligence, thereby reducing the cognitive load on laboratory and clinical staff and accelerating decision-making.

Third, develop strategic supply chain programs that combine localized manufacturing or co-manufacturing arrangements with diversified distributor networks to mitigate trade-related disruptions and tariff exposure. Fourth, adopt an evidence-first commercialization approach that pairs pragmatic clinical studies with real-world performance data; demonstrating impact on antimicrobial stewardship metrics, turnaround times, and treatment pathways will be critical to secure institutional buy-in. Fifth, cultivate partnerships across the One Health spectrum, engaging veterinary diagnostics, pharmaceutical partners, and public health agencies to broaden surveillance coverage and create multi-sector value propositions.

Finally, strengthen customer enablement through consulting and support services that address laboratory workflow optimization, staff training, and data governance. This service-led approach not only accelerates adoption but creates recurring revenue pathways and deeper client relationships. Collectively, these steps position leaders to navigate regulatory complexities, tariff shocks, and rapidly evolving clinical expectations while delivering solutions that materially improve resistance detection and patient care.

A robust multi-method research design combining primary stakeholder interviews, secondary evidence synthesis, data triangulation, and scenario analysis to ensure rigor

The research underpinning this report integrates multiple data collection and validation layers to ensure methodological rigor and relevance. Primary research comprised structured interviews with clinical laboratory directors, procurement leads, diagnostic product managers, and public health officials to capture first-hand perspectives on technology adoption, procurement constraints, and operational priorities. These interviews were supplemented by engagements with service providers and technical specialists to understand implementation challenges and support requirements across diverse laboratory settings.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, public health surveillance reports, and technology white papers to contextualize primary findings and trace the evolution of assay performance characteristics. Where applicable, technical specifications and regulatory filings were examined to validate claims regarding platform capabilities and intended use. Data triangulation was used to cross-check interview inputs with documented evidence and to surface consistent themes across stakeholder groups.

Analytical approaches included segmentation mapping to align technology capabilities with end-user needs, scenario analysis to assess the operational impacts of policy and tariff shifts, and sensitivity testing to identify key commercial levers. Quality control protocols encompassed respondent verification, documentation of data sources, and iterative review cycles with subject matter experts to refine interpretations. Together, this methodology provides a transparent and defensible foundation for the insights and recommendations presented in the report.

Concluding synthesis of technological imperatives, supply chain realities, and strategic priorities that determine success in the evolving AMR diagnostics landscape

In sum, the diagnostics landscape for antimicrobial resistance is entering a phase where technological capability, service integration, and supply chain resilience determine competitive advantage. Advanced sequencing, rapid molecular assays, and mass spectrometry are each playing complementary roles, while software and consulting services are increasingly essential to convert complex outputs into clinically actionable recommendations. Regulatory modernization, stewardship imperatives, and procurement dynamics are shaping adoption pathways across hospitals, reference labs, and research institutions.

Trade policy shifts and tariff measures in 2025 have highlighted vulnerabilities in global reagent and consumable supply chains, prompting manufacturers and buyers to re-evaluate sourcing strategies and invest in mitigations such as localized manufacturing and diversified distribution agreements. Region-specific dynamics in the Americas, Europe Middle East & Africa, and Asia-Pacific will require tailored approaches that reflect differing regulatory regimes, laboratory capacities, and funding mechanisms. The most successful players will combine technological differentiation with demonstrable clinical utility and robust service commitments to support implementation and scale.

Ultimately, stakeholders that act decisively-prioritizing interoperable designs, evidence generation, and resilient commercial models-will be best positioned to meet the evolving needs of clinicians and public health systems while contributing to more effective detection and management of antimicrobial resistance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimicrobial Resistance Diagnostic Market, by Technology

  • 8.1. Mass Spectrometry
  • 8.2. Microarray
  • 8.3. Next Generation Sequencing
    • 8.3.1. Long Read Sequencing
    • 8.3.2. Short Read Sequencing
  • 8.4. Polymerase Chain Reaction (PCR)

9. Antimicrobial Resistance Diagnostic Market, by Product

  • 9.1. Instruments
  • 9.2. Reagents & Consumables
  • 9.3. Software & Services
    • 9.3.1. Services
      • 9.3.1.1. Consulting Services
      • 9.3.1.2. Support Services
    • 9.3.2. Software

10. Antimicrobial Resistance Diagnostic Market, by Test Type

  • 10.1. Genotypic Tests
    • 10.1.1. Targeted Assays
    • 10.1.2. Whole Genome Sequencing
  • 10.2. Phenotypic Tests

11. Antimicrobial Resistance Diagnostic Market, by Sample Type

  • 11.1. Blood Samples
  • 11.2. Respiratory Samples
  • 11.3. Urine Samples
  • 11.4. Wound Swabs

12. Antimicrobial Resistance Diagnostic Market, by Pathogen

  • 12.1. Fungi
  • 12.2. Gram Negative Bacteria
  • 12.3. Gram Positive Bacteria

13. Antimicrobial Resistance Diagnostic Market, by Application

  • 13.1. Human Diagnostics
  • 13.2. Pharmaceutical & Biopharmaceutical
  • 13.3. Veterinary Diagnostics

14. Antimicrobial Resistance Diagnostic Market, by End User

  • 14.1. Academic & Research Institutions
  • 14.2. Diagnostic Centers
  • 14.3. Hospitals & Clinics
  • 14.4. Reference Laboratories

15. Antimicrobial Resistance Diagnostic Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Antimicrobial Resistance Diagnostic Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Antimicrobial Resistance Diagnostic Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Antimicrobial Resistance Diagnostic Market

19. China Antimicrobial Resistance Diagnostic Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. Becton, Dickinson and Company
  • 20.7. Bio-Rad Laboratories, Inc.
  • 20.8. bioMerieux SA
  • 20.9. Bruker Corporation
  • 20.10. Danaher Corporation
  • 20.11. QIAGEN N.V.
  • 20.12. Roche Diagnostics
  • 20.13. Siemens Healthineers AG
  • 20.14. Thermo Fisher Scientific Inc.
  • 20.15. Vela Diagnostics

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LONG READ SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LONG READ SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LONG READ SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SHORT READ SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SHORT READ SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SHORT READ SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SUPPORT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SUPPORT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SUPPORT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TARGETED ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TARGETED ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TARGETED ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PHENOTYPIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PHENOTYPIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PHENOTYPIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESPIRATORY SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESPIRATORY SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESPIRATORY SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY URINE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY URINE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY URINE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY WOUND SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY WOUND SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY WOUND SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FUNGI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FUNGI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FUNGI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY HUMAN DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY HUMAN DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY HUMAN DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 222. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 226. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 255. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 256. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 260. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 262. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 270. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 272. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2